FindTrial
Sign In

Aducanumab

DRUG9 trials

Sponsors

Biogen, Eli Lilly and Company, Ali Rezai

Conditions

Alzheimer DiseaseAlzheimer Disease 1Alzheimer's DiseaseCognitive DysfunctionHealthy VolunteerHealthy VolunteersMild Cognitive ImpairmentMild Cognitive Impairment (MCI)

Early Phase 1

Safety and Feasibility of Exablate Blood-Brain Barrier Disruption for Mild Cognitive Impairment or Mild Alzheimer's Disease Undergoing Standard of Care Monoclonal Antibody (mAb) Therapy
Active, not recruitingNCT05469009
Ali RezaiAlzheimer Disease 1, Mild Cognitive Impairment
Start: 2022-07-14End: 2029-07-01Target: 15Updated: 2026-01-22

Phase 1

Single and Multiple Ascending Dose Study of Aducanumab (BIIB037) in Japanese Participants With Alzheimer's Disease
CompletedNCT02434718
BiogenAlzheimer's Disease
Start: 2015-06-24End: 2016-12-09Updated: 2020-08-21
Absolute Bioavailability of a Single, Fixed Subcutaneous Dose of Aducanumab in Healthy Participants
CompletedNCT02782975
BiogenAlzheimer's Disease
Start: 2016-05-31End: 2016-11-30Updated: 2017-01-13
A Study to Assess Absolute Bioavailability of Aducanumab in Healthy Volunteers
CompletedNCT04924140
BiogenHealthy Volunteers
Start: 2021-06-30End: 2021-10-01Updated: 2023-04-13
A Study to Assess the Pharmacokinetic (PK) Comparability of 2 Fixed Subcutaneous (SC) Doses of Aducanumab (BIIB037) With a Single, Weight-Based Intravenous (IV) Dose in Healthy Volunteers
CompletedNCT05216887
BiogenHealthy Volunteer
Start: 2022-02-01End: 2022-07-27Updated: 2023-04-18

Phase 2

A Study of Aducanumab in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease Dementia to Evaluate the Safety of Continued Dosing in Participants With Asymptomatic Amyloid-Related Imaging Abnormalities
TerminatedNCT03639987
BiogenAlzheimer's Disease, Cognitive Dysfunction
Start: 2018-12-20End: 2019-07-30Updated: 2021-09-16

Phase 3

A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205
TerminatedNCT04241068
BiogenAlzheimer's Disease
Start: 2020-03-02End: 2024-07-22Updated: 2025-02-21
A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4)
CompletedNCT05108922
Eli Lilly and CompanyAlzheimer Disease, Mild Cognitive Impairment (MCI)
Start: 2021-11-16End: 2023-09-19Updated: 2024-11-29
A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease
TerminatedNCT05310071
BiogenAlzheimer's Disease
Start: 2022-06-02End: 2024-08-12Updated: 2025-04-23

Related Papers

Association of Occipital Amyloid PET Burden with ARIA‐E: Exploratory Analyses in Three Clinical Trials of Donanemab
Alzheimer s & Dementia2025-12-01
Association of Occipital Amyloid PET Burden with ARIA‐E: Exploratory Analyses in Three Clinical Trials of Donanemab
Alzheimer s & Dementia2025-12-01
Combination of focused ultrasound blood‐brain barrier opening with Lecanemab therapy in mild Alzheimer's disease
Alzheimer s & Dementia2025-12-01
TRAILBLAZER‐ALZ 4: A phase 3 trial comparing donanemab with aducanumab on amyloid plaque clearance in early, symptomatic Alzheimer's disease
Alzheimer s & Dementia2025-05-0112 citations
Advancing Inclusivity for African American and Hispanic Populations in Alzheimer’s Disease Trials: Understanding Screen Failures from the Aducanumab Confirmatory Trial
Alzheimer s & Dementia2024-12-01
Effect of an 18-month meditation training on cardiovascular risk in older adults: a secondary analysis of the Age-Well randomized controlled trial.
2024-11-16
Reliability of the assessment of the clinical dementia rating scale from the analysis of medical records in comparison with the reference method.
2024-09-0510 citations
ENVISION: A phase 3b/4 randomized, double‐blind, placebo‐controlled, parallel‐group study to verify the clinical benefit of aducanumab in participants with early Alzheimer’s disease
Alzheimer s & Dementia2022-12-013 citations
ENVISION: Increasing diversity of a large phase 3b/4 confirmatory trial of aducanumab to better understand the efficacy and safety among historically underrepresented participants of Alzheimer’s disease research and clinical trials.
Alzheimer s & Dementia2022-12-01
Autopsy Results from the ENGAGE Trial of Aducanumab: Lessons from Co‐pathology
Alzheimer s & Dementia2022-12-01
Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes
JAMA Neurology2022-09-12172 citations
Baseline EMBARK Data From EMERGE, ENGAGE, and PRIME Participants in the EMBARK Redosing Study (N3.002)
Neurology2022-05-031 citations
Ten‐minute cognitive screening tool for mild cognitive impairment and prediction of pathological ß‐amyloid
Alzheimer s & Dementia2021-12-011 citations
Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease
JAMA Neurology2021-11-22539 citations
Predicted Lifetime Health Outcomes for Aducanumab in Patients with Early Alzheimer's Disease.
2021-08-2333 citations